PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31094010-2	2019	Teneligliptin is metabolized by CYP3A4, and glimepiride might be partly metabolized by CYP3A4.	3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine	0-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-38	
30982160-2	2019	Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor with a t1/2 of approximately 24 h and unique pharmacokinetic properties: it is metabolized by cytochrome P450 (CYP) 3A4 and flavin-containing monooxygenase 3 (FMO3), or excreted from the kidney in an unchanged form.	3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine	0-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	165-190	
23855261-10	2014	CYP3A4 and FMO3 are the major enzymes responsible for the metabolism of teneligliptin in humans.	3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine	72-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6	
24726088-1	2014	OBJECTIVE: The aim of this study was to examine the effect of ketoconazole, a potent cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp) inhibitor, on teneligliptin pharmacokinetics and to evaluate the safety of combined administration of teneligliptin with ketoconazole.	3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine	151-164	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-110	
24726088-13	2014	CONCLUSIONS: Because the exposure to teneligliptin in combined administration with ketoconazole, a potent CYP3A4 and P-gp inhibitor, was less than twice that of administration of teneligliptin alone, it is suggested that combined administration of teneligliptin with drugs and foods that inhibit CYP3A4 should not cause a marked increase in exposure.	3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine	37-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112	
34512362-0	2021	Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans.	3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine	70-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	22-28	
34512362-2	2021	FMO3 and CYP3A4 metabolize teneligliptin into teneligliptin sulfoxide.	3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine	27-40	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	9-15	
34512362-6	2021	These results suggest that FMO3 and CYP3A4 polymorphisms affect teneligliptin pharmacokinetics in humans.	3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine	64-77	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-42